



WE CLAIM:

1. A compound of formula (Ia), formula (Ib), formula (IIa) or formula (IIb):



Formula (I)



Formula (II)

or a pharmaceutically acceptable salt thereof:

wherein:

X is a partially saturated aza-containing heteroaryl;

Y is N or CH;

each  $R^1$  is cyano, hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C<sub>1</sub>-C<sub>3</sub> alkyl, -N(R<sup>4</sup>)<sub>2</sub>, -NR<sup>4</sup>C(O)C<sub>1</sub>-C<sub>3</sub> alkyl or cycloalkyl;

Q is a bond, O or NR<sup>4</sup>;


each  $R^2$  is hydrogen or halogen;

each  $R^3$  is hydrogen, halogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

each  $R^4$  is hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl; and

m is 0, 1, 2 or 3;


- The compound of claim 1, wherein the aza-containing heteroaryl is indoliziny, indolyl, isoindolyl, 3H-indolyl, indolinyl, indazolyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinoliziny, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, quinuclidinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, oxazolyl, thiazolyl, imidazolyl, 2-imidazoliny, pyrazolyl, 2-pyrazolinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, or 1,3,5-triazinyl.
- The compound of claim 1, wherein X is:



wherein  $R^1$ , Y and m are as defined in claim 1.

- The compound of claim 3, wherein m is one and  $R^1$  is cyano, hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C<sub>1</sub>-C<sub>3</sub> alkyl, -N(R<sup>4</sup>)<sub>2</sub>, -NR<sup>4</sup>C(O)C<sub>1</sub>-C<sub>3</sub> alkyl or cycloalkyl.
- The compound of claim 4, wherein the halogen is chlorine or fluorine.
- The compound of claim 4, wherein the haloalkyl is trifluoromethyl.


7. The compound of claim 4, wherein the Q is a bond and the C<sub>1</sub>-C<sub>3</sub> alkyl is methyl, ethyl or isopropyl.
8. The compound of claim 4, wherein the Q is O and the C<sub>1</sub>-C<sub>3</sub> alkyl is methyl, ethyl or isopropyl.
9. The compound of claim 4, wherein the Q is N and the C<sub>1</sub>-C<sub>3</sub> alkyl is methyl, ethyl or isopropyl.
10. The compound of claim 4, wherein the each R<sup>4</sup> group of the -N(R<sup>4</sup>)<sub>2</sub> is hydrogen.
11. The compound of claim 4, wherein the each R<sup>4</sup> group of the -N(R<sup>4</sup>)<sub>2</sub> is C1-C3 alkyl.
12. The compound of claim 4, wherein the hydroxyalkyl is hydroxymethyl.
13. The compound of claim 4, wherein the cycloalkyl is cyclopropyl.
14. The compound of claim 3, wherein m is two and each R<sup>1</sup> is independently cyano, halogen, C<sub>1</sub>-C<sub>3</sub> alkyl or cycloalkyl.
15. The compound of claim 14, wherein each R<sup>1</sup> is halogen.
16. The compound of claim 14, wherein one R<sup>1</sup> is cyano and the other R<sup>1</sup> is hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C<sub>1</sub>-C<sub>3</sub> alkyl, -N(R<sup>4</sup>)<sub>2</sub>, -NR<sup>4</sup>C(O)C<sub>1</sub>-C<sub>3</sub> alkyl or cycloalkyl.
17. The compound of claim 1, wherein X is:





and wherein each R<sup>1</sup> is hydrogen or methyl.

18. The compound of claim 17, wherein each R<sup>1</sup> is methyl.

19. The compound according to any one of claims 1-18, wherein R<sup>2</sup> is halogen.
20. The compound of claim 19, wherein the halogen is chlorine.
21. The compound according to any one of claims 1-20, wherein R<sup>3</sup> is halogen or C<sub>1</sub>-C<sub>3</sub> alkyl.
22. The compound of claim 21, wherein the halogen is fluorine.
23. The compound of claim 21, wherein the C<sub>1</sub>-C<sub>3</sub> alkyl is methyl.
24. The compound of claim 1, wherein the compound is selected from the group consisting of:







and pharmaceutically acceptable salts thereof.

25. A pharmaceutical composition, comprising an effective amount of a compound according to any one of claims 1-24, and a pharmaceutically acceptable excipient.
26. A method for inhibiting ROCK activity in a cell, comprising contacting the cell in which inhibition of ROCK activity is desired with a therapeutically effective amount of a compound of claim 1.
27. The method of claim 26, wherein the contacting occurs in vivo.
28. The method of claim 26 or 27, wherein the therapeutically effective amount of the compound is between 0.01 to 300 mg/kg per day.
29. The method of claim 28, wherein the therapeutically effective amount of the compound is between 0.1 to 100 mg/kg per day.
30. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating cerebral cavernous malformation syndrome (CCM) in a patient.
31. The use of Claim 30, wherein the therapeutically effective amount of the compound is between 0.01 to 300 mg/kg per day.

32. The use of Claim 31, wherein the therapeutically effective amount of the compound is between 0.1 to 100 mg/kg per day.
33. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating a cardiovascular disease associated with increased vasotension in a patient in need thereof.
34. The use of claim 33, wherein the cardiovascular disease is hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina or erectile dysfunction.
35. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating diseases involving elevated non-vascular smooth muscle contractility in a patient in need thereof.
36. The use of claim 35, wherein the disease involving elevated non-vascular smooth muscle contractility is asthma or glaucoma.